You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
PharmaCyte, which develops therapies for cancer and diabetes, will be responsible for development and commercialization of tests based on the technology.
Biomerica intends to manufacture ELISA test technology licensed from Mt. Sinai. The firm said it has capacity to manufacture 1 million tests per month.
The firm licensed the assay for detecting SARS-CoV-2 from Hackensack Meridian Health and will adapt it for the T2Dx instrument.
The test can be completed in 15 minutes using an app and will be distributed with Scanwell's telehealth partner Lemonaid Health.
The deal aims to create novel products to help diagnostic companies manage risks of interferences in current test designs.
The deal gives DiaSorin the exclusive rights to TTP's sample-to-answer diagnostic system for human in vitro diagnostic applications.
The PAVmed subsidiary will have the option to license the biomarkers for a year after the completion of a Phase II study evaluating their accuracy.
Since 2017, the companies have been jointly developing an in vitro assay for measurement of sTREM-1 in plasma samples of septic shock patients.
As part of the expanded deal, Oncore will offer StageZero's BreastSentry and Prostate Health Index tests, as well as ColonSentry.
While NanoString will commercialize its nCounter for research use applications, Veracyte will move its current assays onto the platform to reach a global audience.